Effectiveness of infliximab after adalimumab failure in Crohn's disease.
OBJECTIVE
To evaluate the effectiveness of infliximab as a second-line therapy in Crohn's disease patients after adalimumab failure.


METHODS
A historical cohort study in a community-based gastroenterology practice evaluated Crohn's disease patients treated with infliximab (induction plus maintenance) after adalimumab failure. Patients were identified using a large Spanish database (ENEIDA).


RESULTS
We included 15 Crohn's disease patients who received infliximab after adalimumab failure. Five patients discontinued adalimumab due to loss of response, 3 due to adverse events and 7 due to partial response. After infliximab therapy was started, all patients who had interrupted adalimumab due to loss of efficacy regained response. All patients who discontinued adalimumab due to adverse events responded to infliximab and maintained this response; one of these patients had an uneventful course on infliximab, but 2 developed adverse events. None of the 7 patients who interrupted adalimumab due to partial response reached remission with infliximab.


CONCLUSIONS
Switching from adalimumab to infliximab may be useful in patients who develop adverse effects or loss of response, however, the benefit of infliximab in primary nonresponders was not established.
Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 28006 Madrid, Spain. mariachs2005@gmail.com
María
M
Chaparro
Montserrat
M
Andreu
Manuel
M
Barreiro-de Acosta
Esther
E
García-Planella
Elena
E
Ricart
Eugeni
E
Domènech
María
M
Esteve
Olga
O
Merino
Pilar
P
Nos
Mireia
M
Peñalva
Javier P
JP
Gisbert
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D003424:Crohn Disease / Q000188:drug therapy*; D016208:Databases, Factual; D005260:Female; D005762:Gastroenterology / Q000379:methods; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000378:metabolism; D000069285:Infliximab; D008297:Male; D012074:Remission Induction; D013030:Spain; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D007155:Immunologic Factors; D000069285:Infliximab; D000068879:Adalimumab